Table: Santen Pharm -2025/26 group results (IFRS)
12/05/2026 07:33
May 12 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2026 Mar 31, 2025 Mar 31, 2027 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 291.62 300.00 311.00
(-2.8 pct) (-0.6 pct) (+6.6 pct)
Operating 47.80 46.88 49.50
(+2.0 pct) (+21.6 pct) (+3.6 pct)
Pretax
Net 37.37 36.26 40.00
(+3.1 pct) (+36.1 pct) (+7.0 pct)
EPS Basic 114.04 yen 103.98 yen 124.42 yen
EPS Diluted 113.80 yen 103.68 yen
Ann Div 38.00 yen 36.00 yen 42.00 yen
-Q2 Div 19.00 yen 17.00 yen 21.00 yen
-Q4 Div 19.00 yen 19.00 yen 21.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T